Cited by 1,674Breast Cancer Treatment StudiesEstrogen and related hormone effectsEndometrial and Cervical Cancer Treatments

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F·2010·The Lancet Oncology

DOI 10.1016/s1470-2045(10)70257-6

Open this paper in CoChat — free account

Abstract

Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months.Methods We used a proportional hazards model to assess the primary endpoint of disease-free survival, and the secondary endpoints of time to recurrence, time to distant recurrence, incidence of new contralateral breast cancer, overall survival, and death with or without recurrence in all randomised patients (anastrozole n=3125, tamoxifen n=3116) and hormone-receptor-positive patients (anastrozole n=2618, tamoxifen n=2598). After treatment completion, we continued to collect data on fractures and serious adverse events in a masked fashion (safety population: anastrozole n=3092, tamoxifen n=3094). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.Findings Patients were followed up for a median of 120 months (range 0-145); there were 24,522 woman-years of follow-up in the anastrozole group and 23,950 woman-years in the tamoxifen group. In the full study population, there were significant improvements in the anastrozole group compared with the tamoxifen group for disease-free survival (hazard ratio [HR] 0·91, 95% CI 0·83-0·99; p=0·04), time to recurrence (0·84, 0·75-0·93; p=0·001), and time to distant recurrence (0·87, 0·77-0·99; p=0·03). For hormone-receptor-positive patients, the results were also significantly in favour of the anastrozole group for disease-free survival (HR 0·86, 95% CI 0·78-0·95; p=0·003), time to recurrence (0·79, 0·70-0·89; p=0·0002), and time to distant recurrence (0·85, 0·73-0·98; p=0·02). In hormone-receptor-positive patients, absolute differences in time to recurrence between anastrozole and tamoxifen increased over time (2·7% at 5 years and 4·3% at 10 years) and recurrence rates remained significantly lower on anastrozole than tamoxifen after treatment completion (HR 0·81, 95% CI 0·67-0·98; p=0·03), although the carryover benefit was smaller after 8 years. There was weak evidence of fewer deaths after recurrence with anastrozole compared with tamoxifen treatment in the hormone-receptor-positive subgroup (HR 0·87, 95% CI 0·74-1·02; p=0·09), but there was little difference in overall mortality (0·95, 95% CI 0·84-1·06; p=0·4). Fractures were more frequent during active treatment in patients receiving anastrozole than those receiving tamoxifen (451 vs 351; OR 1·33, 95% CI 1·15-1·55; p<0·0001), but were similar in the post-treatment follow-up period (110 vs 112; OR 0·98, 95% CI 0·74-1·30; p=0·9). Treatment-related serious adverse events were less common in the anastrozole group than the tamoxifen group (223 anastrozole vs 369 tamoxifen; OR 0·57, 95% CI 0·48-0·69; p<0·0001), but were similar after treatment completion (66 vs 78; OR 0·84, 95% CI 0·60-1·19; p=0·3). No differences in non-breast cancer causes of death were apparent and the incidence of other cancers was similar between groups (425 vs 431) and continue to be higher with anastrozole for colorectal (66 vs 44) and lung cancer (51 vs 34), and lower for endometrial cancer (six vs 24), melanoma (eight vs 19), and ovarian cancer (17 vs 28). No new safety concerns were reported.Interpretation These data confirm the long-term superior efficacy and safety of anastrozole over tamoxifen as initial adjuvant therapy for postmenopausal women with hormone-sensitive early breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(10)70257-6

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Self-citation
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
Self-citation
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
Nabholtz, J., Buzdar, A. U., Pollak, M., Harwin, W. N., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 989
Self-citation
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Williams, N. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 918
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Coombes, R. C., Kilburn, L., Snowdon, C. F., Paridaens, R., Coleman, R., Jones, S., Jassem, J., van de Velde, C., Delozier, T., Álvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 901
Self-citation

Show all 27 references

Sorted by citations

Items 101–200 of 1,000

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis
Hadji, P. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.07.013 · Cited by 166
Management of breast cancer with targeted agents: importance of heterogenicity
Cosimo, S. D., & Baselga, J. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.234 · Cited by 159
Breast Cancer Screening With Mammography Plus Ultrasonography or Magnetic Resonance Imaging in Women 50 Years or Younger at Diagnosis and Treated With Breast Conservation Therapy
Cho, N., Han, W., Han, B., Bae, M. S., Ko, E. S., Nam, S. J., Chae, E. Y., Lee, J. W., Kim, S. H., Kang, B. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1256 · Cited by 162
Targeted Therapy for Breast Cancer Prevention
den Hollander, P., Savage, M. I., & Brown, P. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00250 · Cited by 161
Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer
Cristofanilli, M., Valero, V., Mangalik, A., Royce, M., Rabinowitz, I., Arena, F. P., Kroener, J. F., Curcio, E., Watkins, C. L., Bacus, S. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2282 · Cited by 156
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age
Mook, S., Schmidt, M. K., Weigelt, B., Kreike, B., Eekhout, I., van de Vijver, M. J., Glas, A. M., Floore, A. N., Rutgers, E. J. T., & Veer, L. V. ‘. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp388 · Cited by 154
A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
Fox, E. M., Miller, T. W., Balko, J. M., Kuba, M. G., Sanchez, V. M., Smith, R. A., Liu, S., Gonzalez-Angulo, A. M., Mills, G. B., Ye, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1295 · Cited by 154
Cancer-associated bone disease
Rizzoli, R., Body, J. J., Brandi, M. L., Cannata-Andía, J. B., Chappard, D., Maghraoui, A. E., Glüer, C.-C., Kendler, D., Napoli, N., Παπαϊωάννου, Α., et al. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2530-3 · Cited by 155
Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association
Okwuosa, T. M., Morgans, A. K., Rhee, J., Reding, K. W., Maliski, S. L., Plana, J.-C., Volgman, A. S., Moseley, K. F., Porter, C., & Ismail-Khan, R. R. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000082 · Cited by 150
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
Vogel, V. G. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.1.51 · Cited by 148
Perceptions of Contralateral Breast Cancer: An Overestimation of Risk
Abbott, A. M., Rueth, N. M., Pappas-Varco, S., Kuntz, K. M., Kerr, E. H., & Tuttle, T. M. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1914-x · Cited by 147
Bone health during endocrine therapy for cancer
Rachner, T. D., Coleman, R. E., Hadji, P., & Hofbauer, L. C. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30047-0 · Cited by 148
The natural history of hormone receptor-positive breast cancer.
Lim, E., Metzger, O., & Winer, E. P. (2012) · PubMed · Cited by 146
Current management of lesions associated with an increased risk of breast cancer
Morrow, M., Schnitt, S. J., & Norton, L. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.8 · Cited by 143
Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study
Colleoni, M. A., Giobbie‐Hurder, A., Regan, M. M., Thurlimann, B. J. K., Mouridsen, H. T., Mauriac, L., Forbes, J., Paridaens, R., Láng, I., Smith, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6455 · Cited by 143
Self-citation
Screening MRI in Women With a Personal History of Breast Cancer
Lehman, C. D., Lee, J. M., DeMartini, W. B., Hippe, D. S., Rendi, M. H., Kalish, G., Porter, P. L., Gralow, J. R., & Partridge, S. C. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv349 · Cited by 144
Obesity and breast cancer – role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue
Gérard, C., & Brown, K. A. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.09.014 · Cited by 136
The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer
Jordan, V. C. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0448 · Cited by 135
Clinical significance of estrogen receptor phosphorylation
Murphy, L. C., Seekallu, S. V., & Watson, P. H. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0070 · Cited by 133
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer
Simigdala, N., Gao, Q., Pancholi, S., Røberg‐Larsen, H., Zvelebil, M., Ribas, R., Folkerd, E. J., Thompson, A., Bhamra, A., Dowsett, M., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0713-5 · Cited by 137
Self-citation
Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy
Hadji, P. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.02.001 · Cited by 137
Overview of Parametric Survival Analysis for Health-Economic Applications
Ishak, K. J., Kreif, N., Benedict, Á., & Muszbek, N. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0064-3 · Cited by 133
Obesity as potential breast cancer risk factor for postmenopausal women
Mohanty, S. S., & Mohanty, P. K. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.09.006 · Cited by 132
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review
Matthews, A., Stanway, S. J., Farmer, R. E., Strongman, H., Thomas, S., Lyon, A. R., Smeeth, L. L., & Bhaskaran, K. (2018) · BMJ · doi:10.1136/bmj.k3845 · Cited by 131
Mechanisms of bone metastases of breast cancer
Suva, L. J., Griffin, R. J., & Makhoul, I. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0012 · Cited by 131
Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
Bliss, J. M., Kilburn, L., Coleman, R. E., Forbes, J., Coates, A. S., Jones, S. E., Jassem, J., Delozier, T., ANDERSEN, J. E., Paridaens, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7899 · Cited by 130
Self-citation
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
Bijl, M. J., van Schaik, R. H. N., Lammers, L. A., Albert Hofman, D., Vulto, A. G., van Gelder, T., Stricker, B. H. C., & Visser, L. E. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0272-2 · Cited by 126
Genomic profiling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., Sanchez, V. M., Ericsson, P. I. G., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7993 · Cited by 126
The patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer
Hadji, P., Blettner, M., Harbeck, N., Jackisch, C., Lück, H.-J., Windemuth-Kieselbach, C., Zaun, S., & Kreienberg, R. (2013) · Annals of Oncology · doi:10.1093/annonc/mds653 · Cited by 122
Immediate post-mastectomy breast reconstruction followed by radiotherapy: risk factors for complications
Cowen, D. M., Groß, E., Rouannet, P., Teissier, E., Ellis, S. B., Resbeut, M., Tallet, A. R., Cowen, V. V., Azria, D., & Hannoun‐Lévi, J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0791-5 · Cited by 122
Molecular Drivers of Onco type DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
Buus, R., Šestak, I., Kronenwett, R., Ferree, S., Schnabel, C. A., Baehner, F. L., Mallon, E., Cuzick, J. M., & Dowsett, M. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00853 · Cited by 122
Self-citation
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
Gaillard, S. L., & Stearns, V. (2011) · Breast Cancer Research · doi:10.1186/bcr2818 · Cited by 124
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II)
Jenkins, V. A., Ambroisine, L., Atkins, L., Cuzick, J. M., Howell, A., & Fallowfield, L. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70207-9 · Cited by 120
Self-citation
Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer
Folkerd, E. J., Dixon, J. M., Renshaw, L., A’Hern, R., & Dowsett, M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0273 · Cited by 118
Self-citation
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
Smith, I., Yardley, D. A., Burris, H. A., Boer, R. D., Amadori, D., McIntyre, K. J., Ejlertsen, B., Gnant, M., Jonat, W., Pritchard, K. I., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2871 · Cited by 117
Self-citation
Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and –resistant breast cancer cells
Chan, H. J., Petrossian, K., & Chen, S. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.018 · Cited by 123
Molecular therapy of breast cancer: progress and future directions
Lin, S., Chen, J., Mazumdar, M., Poirier, D., Wang, C., Azzi, A., & Zhou, M. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.92 · Cited by 119
GDNF–RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase Inhibitors
Morandi, A., Martin, L., Gao, Q., Pancholi, S., Mackay, A. G., Robertson, D. M., Zvelebil, M., Dowsett, M., Plaza-Menacho, I., & Isacke, C. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4265 · Cited by 120
Self-citation
‘Taking Control of Cancer’: Understanding Women’s Choice for Mastectomy
Covelli, A. M., Baxter, N. N., Fitch, M. I., McCready, D. R., & Wright, F. C. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4033-7 · Cited by 123
Biomarkers in Breast Cancer
Duffy, M. J., Walsh, S. M., McDermott, E. W. M., & Crown, J. P. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.05.001 · Cited by 120
Mechanisms of endocrine therapy resistance in breast cancer
Rasha, F. A., Sharma, M., & Pruitt, K. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111322 · Cited by 119
Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis
Portschy, P. R., Kuntz, K. M., & Tuttle, T. M. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju160 · Cited by 115
Physical Activity During and After Adjuvant Treatment for Breast Cancer: An Integrative Review of Women’s Experiences
Browall, M., Mijwel, S., Rundqvist, H., & Wengström, Y. (2016) · Integrative Cancer Therapies · doi:10.1177/1534735416683807 · Cited by 111
Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications
D’Oronzo, S., Stucci, L. S., Tucci, M., & Silvestris, F. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.09.003 · Cited by 112
Bone Health in Adult Cancer Survivorship
Lustberg, M. B., Reinbolt, R. E., & Shapiro, C. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2097 · Cited by 111
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms
Peng, M., Darko, K. O., Tao, T., Huang, Y., Su, Q., He, C., Yin, T., Liu, Z., & Yang, X. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.005 · Cited by 111
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Ruhstaller, T., Giobbie‐Hurder, A., Colleoni, M. A., Jensen, M., Ejlertsen, B., de Azambuja, E., Neven, P., Láng, I., Jakobsen, E. H., Gladieff, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00440 · Cited by 111
Research Resource: Nuclear Receptors as Transcriptome: Discriminant and Prognostic Value in Breast Cancer
Muscat, G. E. O., Eriksson, N. A., Byth, K., Loi, S., Graham, J. D., Jindal, S., Davis, M. J., Clyne, C. D., Funder, J. W., Simpson, E. R., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1265 · Cited by 111
The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
Zhang, A., Wang, X., Fan, C., & Mao, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.687244 · Cited by 110
Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients
Yin, W., Lu, J.-S., Di, G., Lin, Y.-P., Zhou, L.-H., Liu, G., Wu, J., Shen, K.-W., Han, Q., Shen, Z., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0096-0 · Cited by 109
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved
Lønning, P. E., & Eikesdal, H. P. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0099 · Cited by 111
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
O’Brien, N. A., Conklin, D. F., Beckmann, R. P., Luo, T., Chau, K., Thomas, J. D., Nulty, A. M., Marchal, C. C., Kalous, O., von Euw, E., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0290 · Cited by 108
EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy
Milanezi, F., Carvalho, S., & Schmitt, F. C. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.4.417 · Cited by 109
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial
Cheung, A. M., Tile, L., Cardew, S., Pruthi, S., Robbins, J. A., TOMLINSON, G. A., Kapral, M. K., Khosla, S., Majumdar, S., ERLANDSON, M. C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70389-8 · Cited by 107
Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen
Sanchez‐Spitman, A., Swen, J. J., Dezentjé, V. O., Moes, D. J. A. R., Gelderblom, H. A. J., & Guchelaar, H. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1610390 · Cited by 110
Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials
Šeruga, B., Sterling, L., Wang, L. E., & Tannock, I. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9624 · Cited by 110
Preventive therapy for cancer
Cuzick, J. M. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30536-3 · Cited by 108
Self-citation
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper
Rizzoli, R., Body, J., DeCensi, A., Reginster, J., Piscitelli, P., & Brandi, M. L. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1870-0 · Cited by 106
A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance
Miller, T. W., Balko, J. M., Ghazoui, Z. F., Dunbier, A. K., Anderson, H., Dowsett, M., Gonzalez-Angulo, A. M., Mills, G. B., Miller, W. R., Wu, H., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2567 · Cited by 104
Self-citation
Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
Wang, L., Ellsworth, K. A., Moon, I., Pelleymounter, L. L., Eckloff, B. W., Martin, Y. N., Fridley, B. L., Jenkins, G. D., Batzler, A. J., Suman, V. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3224 · Cited by 105
Self-citation
The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer
Zhou, W., Ni, T. K., Wronski, A., Glass, B., Skibinski, A., Beck, A. H., & Kuperwasser, C. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.006 · Cited by 102
Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity
Reddy, S. M., Barcenas, C. H., Sinha, A. K., Hsu, L., Moulder, S. L., Tripathy, D., Hortobágyi, G. N., & Valero, V. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.379 · Cited by 102
The importance of long-term follow up of participants in clinical trials
Cuzick, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02038-4 · Cited by 101
Self-citation
Hormonal therapy in breast cancer: A model disease for the personalization of cancer care
Puhalla, S., Bhattacharya, S., & Davidson, N. E. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.003 · Cited by 105
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
Geisler, J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.58 · Cited by 101
Breast cancer: Current and future endocrine therapies
Palmieri, C., Patten, D. K., Januszewski, A. P., Zucchini, G., & Howell, S. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.001 · Cited by 102
Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor–Induced Musculoskeletal Pain: SWOG S0927
Hershman, D. L., Unger, J. M., Crew, K. D., Awad, D., Dakhil, S. R., Gralow, J. R., Greenlee, H., Lew, D. L., Minasian, L. M., Till, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5595 · Cited by 101
Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects
Tenti, S., Correale, P., Cheleschi, S., Fioravanti, A., & Pirtoli, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165625 · Cited by 99
Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer
Hackshaw, A. K., Roughton, M., Forsyth, S., Monson, K., Reczko, K., Sainsbury, R., & Baum, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2933 · Cited by 99
Self-citation
Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group
Dubsky, P. C., Jakesz, R., Mlineritsch, B., Pöstlberger, S., Samonigg, H., Kwasny, W., Tausch, C., Stöger, H., Haider, K., Fitzal, F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8993 · Cited by 99
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors
Bacci, M., Giannoni, E., Fearns, A., Ribas, R., Gao, Q., Taddei, M. L., Pintus, G., Dowsett, M., Isacke, C. M., Martin, L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2038 · Cited by 98
Self-citation
Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts
Cottu, P. H., Marangoni, E., Assayag, F., de Crémoux, P., Vincent‐Salomon, A., Guyader, C., de Plater, L., Ganem‐Elbaz, C., Karboul, N., Fontaine, J. J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1815-5 · Cited by 96
Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis
Hadji, P., Ziller, V., Kyvernitakis, I., Bauer, M. W., Haas, G., Schmidt, N., & Kostev, K. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2417-1 · Cited by 92
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
Šestak, I., Martín, M., Dubsky, P. C., Kronenwett, R., Rojo, F., Cuzick, J. M., Filipits, M., Ruı́z, A., Gradishar, W. J., Soliman, H. H., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05226-8 · Cited by 95
Self-citation
Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue
Lester, J., Pahouja, G., Andersen, B. L., & Lustberg, M. B. (2015) · Journal of Personalized Medicine · doi:10.3390/jpm5020050 · Cited by 93
Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells
Gattelli, A., Nalvarte, I., Boulay, A., Roloff, T. C., Schreiber, M., Carragher, N. O., Macleod, K., Schlederer, M., Lienhard, S., Kenner, L., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302625 · Cited by 92
Molecular cancer prevention: Current status and future directions
Maresso, K. C., Tsai, K. Y., Brown, P. H., Szabo, E. M., Lippman, S. M., & Hawk, E. T. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21287 · Cited by 92
A woman's heart
Ewer, M. S., & Glück, S. (2009) · Cancer · doi:10.1002/cncr.24219 · Cited by 91
AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells
Hampsch, R. A., Wells, J. D., Traphagen, N. A., McCleery, C. F., Fields, J. L., Shee, K., Dillon, L. M., Pooler, D. B., Lewis, L. D., Demidenko, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0269 · Cited by 91
Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice
Ziogas, D. E., & Roukos, D. H. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0436-2 · Cited by 92
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers
Raghav, K. P. S., Hernandez-Aya, L. F., Lei, X. J., Chávez‐MacGregor, M., Meric‐Bernstam, F., Buchholz, T. A., Şahin, A. A., Do, K.-A., Hortobágyi, G. N., & Gonzalez-Angulo, A. M. (2011) · Cancer · doi:10.1002/cncr.26431 · Cited by 90
Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer
Dent, S. F., Gaspo, R., Kissner, M., & Pritchard, K. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1351-3 · Cited by 90
Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation
Fox, E. M., Kuba, M. G., Miller, T. W., Davies, B. R., & Arteaga, C. L. (2013) · Breast Cancer Research · doi:10.1186/bcr3449 · Cited by 90
Clinical Decision Support Systems in Breast Cancer: A Systematic Review
Mazo, C., Kearns, C., Mooney, C., & Gallagher, W. M. (2020) · Cancers · doi:10.3390/cancers12020369 · Cited by 89
Endocrine Therapy for Early Breast Cancer: Updated Review.
Tremont, A., Lu, J., & COLE, J. T. (2017) · PubMed Central · Cited by 88
Suppression of Invasion and Metastasis of Triple-Negative Breast Cancer Lines by Pharmacological or Genetic Inhibition of Slug Activity
Ferrari‐Amorotti, G., Chiodoni, C., Shen, F., Cattelani, S., Soliera, A. R., Manzotti, G., Grisendi, G., Dominici, M., Rivasi, F., Colombo, M. P., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.10.006 · Cited by 88
Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer
Bacci, M., Lorito, N., Ippolito, L., Ramazzotti, M., Luti, S., Romagnoli, S., Parri, M., Bianchini, F., Cappellesso, F., Virga, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.010 · Cited by 88
Rational management of endocrine resistance in breast cancer
Hurvitz, S. A., & Pietras, R. J. (2008) · Cancer · doi:10.1002/cncr.23875 · Cited by 87
Tracking progesterone receptor-mediated actions in breast cancer
Knutson, T. P., & Lange, C. A. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.010 · Cited by 91
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
Lundgren, K., Brown, M., Pineda, S., Cuzick, J. M., Salter, J., Zabaglo, L. A., Howell, A., Dowsett, M., Landberg, G., & the TransATAC investigators (2012) · Breast Cancer Research · doi:10.1186/bcr3161 · Cited by 87
Self-citation
The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy
Peppone, L. J., Janelsins, M. C., Kamen, C. S., Mohile, S. G., Sprod, L. K., Gewandter, J. S., Kirshner, J. J., Gaur, R., Ruzich, J. C., Esparaz, B. T., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3351-1 · Cited by 89
Antiestrogens and their therapeutic applications in breast cancer and other diseases.
Ali, S., Buluwela, L., & Coombes, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-052209-100305 · Cited by 89
Cancer Treatment and Bone Health
Handforth, C., D’Oronzo, S., Coleman, R. E., & Brown, J. E. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0369-x · Cited by 93
Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)
Oberguggenberger, A., Michael, H., Sztankay, M. J., Meraner, V., Beer, B., Oberacher, H., Giesinger, J. M., Kemmler, G., Egle, D., Gamper, E., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1378-5 · Cited by 84
Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer
Friese, C. R., Pini, T. M., Li, Y., Abrahamse, P. H., Graff, J. J., Hamilton, A. S., Jagsi, R., Janz, N. K., Hawley, S. T., Katz, S. J., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2499-9 · Cited by 89
A transcriptome-wide Mendelian randomization study to uncover tissue-dependent regulatory mechanisms across the human phenome
Richardson, T. G., Hemani, G., Gaunt, T. R., Relton, C. L., & Smith, G. D. (2020) · Nature Communications · doi:10.1038/s41467-019-13921-9 · Cited by 84
Roles for miRNAs in endocrine resistance in breast cancer
Muluhngwi, P., & Klinge, C. M. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0355 · Cited by 89
Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
Hayes, D. F., Stearns, V., Rae, J. M., & Flockhart, D. A. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn271 · Cited by 84
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial
Eastell, R., Adams, J. E., Clack, G., Howell, A., Cuzick, J. M., Mackey, J. R., Beckmann, M. W., & Coleman, R. E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq541 · Cited by 84
Self-citation
Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients
Foglietta, J., Inno, A., Iuliis, F. D., Sini, V., Duranti, S., Turazza, M., Tarantini, L., & Gori, S. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.07.003 · Cited by 88

Authors: Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F.
Affiliations: University of London (GB)
Cancer Research UK (GB)
The University of Texas MD Anderson Cancer Center (US)
Royal Marsden Hospital (GB)
University of Newcastle Australia (AU)
Corresponding author: Cuzick, Jack
ORCID: Cuzick, Jack
Baum, Michael
Buzdar, Aman
Howell, Anthony
Dowsett, Mitch
Forbes, John F
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2010-12
Volume: 11
Issue: 12
Pages: 1135-1141
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(10)70257-6
OpenAlex: W2112780046
Cited by: 1,674
References: 27
Citations by year: 2026: 21 · 2025: 35 · 2024: 50 · 2023: 54 · 2022: 63 · 2021: 64 · 2020: 85 · 2019: 66 · 2018: 85 · 2017: 98 · 2016: 101 · 2015: 116 · 2014: 125 · 2013: 148 · 2012: 121
FWCI: 51.63
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Research Explorer (The University of Manchester) (submittedVersion)
NOVA (University of Newcastle Australia) (submittedVersion)
Funders: AstraZeneca
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords: anastrozole, tamoxifen, adjuvant endocrine therapy, early breast cancer, postmenopausal women, disease-free survival, time to recurrence, distant recurrence, hormone receptor-positive breast cancer, contralateral breast cancer, overall survival, fracture risk, long-term outcomes, ATAC trial, aromatase inhibitors, selective estrogen receptor modulators, breast cancer recurrence
MeSH terms: Anastrozole, Administration, Oral, Breast Neoplasms, Female, Follow-Up Studies, Humans, Neoplasm Staging, Nitriles, Tamoxifen, Triazoles, Treatment Outcome, Chemotherapy, Adjuvant, Postmenopause, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks